|
Confocal data analysis
|
|---|
|
Confocal data: young (n = 17) versus old (= 17) healthy individuals
|
|---|
| |
Marker
|
Healthy clot CV data (age-controlled for T2D)
|
Healthy young clot CV data
|
P
|
|---|
|
%; median; STD
|
ThT
|
1.30 (± 0.61)
|
1.42 (± 0.64)
|
P = 0.21
|
|
Amytracker 480
|
0.89 (± 0.48)
|
0.78 (± 1.04)
|
P = 0.08
|
|
Amytracker 680
|
1.30 (± 0.46)
|
1.34 (± 0.77)
|
P = 0.94
|
|
Confocal data: Age-controlled healthy individuals (n = 17) versus type 2 diabetes individuals (N = 33)
|
|---|
| |
Marker
|
Healthy clot CV data (age-controlled)
|
Type 2 diabetes clot CV data
|
P
|
|---|
|
Median; STD
|
ThT
|
1.30 (± 0.61)
|
2.52 (± 1.16)
|
P < 0.0001
|
|
Amytracker 480
|
0.89 (± 0.48)
|
1.44 (± 0.50)
|
P < 0.0001
|
|
Amytracker 680
|
1.30 (± 0.46)
|
2.30 (± 0.67)
|
P < 0.0001
|
|
Confocal data: Treated versus untreated diabetes data (n = 15)
|
|---|
| |
Marker
|
Untreated T2D
|
T2D plasma treated with 8 ng L−1 LBP and 250 µM ergothioneine
|
P
|
|---|
|
Median; STD
|
ThT
|
2.23 (± 1.21)
|
1.58 (± 0.78)
|
P = 0.0008
|
|
Amytracker 480
|
1.25 (± 0.42)
|
1.25 (± 0.54)
|
P = 0.37
|
|
Amytracker 680
|
1.91 (± 0.73)
|
1.37 (± 0.55)
|
P = 0.0009
|
| |
Marker
|
Untreated T2D
|
T2D plasma treated with 20 ng L−1 LBP and 250 µM ergothioneine
|
P
|
|---|
|
Median; STD
|
ThT
|
2.23 (± 1.21)
|
1.75 (± 0.61)
|
P = 0.007
|
|
Amytracker 480
|
1.25 (± 0.42)
|
0.90 (± 0.34)
|
P = 0.0001
|
|
Amytracker 680
|
1.91 (± 0.73)
|
1.50 (± 0.37)
|
P = 0.0002
|
| |
Marker
|
Untreated T2D
|
T2D plasma treated with 30 ng L−1 LBP
|
P
|
|---|
|
Median; STD
|
ThT
|
2.23 (± 1.21)
|
1.87 (± 0.60)
|
P = 0.033
|
|
Amytracker 480
|
1.25 (± 0.42)
|
1.45 (± 2.98)
|
P = 0.036
|
|
Amytracker 680
|
1.91 (± 0.73)
|
1.70 (± 0.60)
|
P = 0.042
|
- Statistical analysis was performed with the Mann–Whitney U test, using the STATSDIRECT (version 2.8.0) software
